




BCMA: essential for survival of plasma cells, including malignant myeloma cells

Role in normal and malignant cells

B-cell maturation antigen (BCMA), a transmembrane protein, is a member of the tumor necrosis factor (TNF) receptor superfamily. BCMA is predominantly expressed on plasma cells, including malignant myeloma cells, and is therefore critical to the survival of these cell types.¹⁻⁶



Preclinical evidence

Preclinical studies have shown that BCMA is essential to the survival of plasma cells, including myeloma cells.¹⁻³

Multiple approaches to target BCMA

BCMA is a promising target antigen in multiple myeloma that is being investigated in the context of multiple different modalities that target the pathway, including bivalent antibodies, CAR T cells, and conjugated antibodies.^{1,2,4,6}

The safety and efficacy of the agents and/or uses under investigation have not been established. There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses being investigated.

CAR=chimeric antigen receptor.

1. Seckinger A et al. *Cancer Cell*. 2017;31:396-410. 2. Tai Y, Anderson K. *Immunotherapy*. 2015;7:1187-1199. 3. O'Connor BP et al. *J Exp Med*. 2004;199:91-98. 4. Carpenter RO et al. *Clin Cancer Res*. 2013;19:2048-2060. 5. June H et al. *Science*. 2018;359:1361-1365. 6. Jackson HJ et al. *Nat Rev Clin Oncol*. 2016;13:370-383.